[日本語] English
文献
- EMDB/PDB/SASBDBから引用されている文献のデータベース -

+
検索条件

キーワード
構造解析手法
著者・登録者
ジャーナル
IF

-
Structure paper

タイトルInterrogating HIV Integrase for Compounds that Bind- a Sampl Challenge.
ジャーナル・号・ページJ. Comput. Aided Mol. Des., Vol. 28, Page 347-, Year 2014
掲載日2013年11月11日 (構造データの登録日)
著者Peat, T.S. / Dolezal, O. / Newman, J. / Mobley, D. / Deadman, J.J.
リンクJ. Comput. Aided Mol. Des. / PubMed:24532034
手法X線回折
解像度1.65 - 2.15 Å
構造データ

PDB-4ce9:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 2.1 Å

PDB-4cea:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.8 Å

PDB-4ceb:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.75 Å

PDB-4cec:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.75 Å

PDB-4ced:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.75 Å

PDB-4cee:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.8 Å

PDB-4cef:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.7 Å

PDB-4ceo:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.9 Å

PDB-4ceq:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.7 Å

PDB-4cer:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.7 Å

PDB-4ces:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.85 Å

PDB-4cez:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.7 Å

PDB-4cf0:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.85 Å

PDB-4cf1:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.95 Å

PDB-4cf2:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.95 Å

PDB-4cf8:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.65 Å

PDB-4cf9:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 2.1 Å

PDB-4cfa:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 2.05 Å

PDB-4cfb:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.95 Å

PDB-4cfc:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.9 Å

PDB-4cfd:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 2.15 Å

PDB-4cgd:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 2 Å

PDB-4cgf:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.7 Å

PDB-4cgg:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.75 Å

PDB-4cgh:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.76 Å

PDB-4cgi:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 2.07 Å

PDB-4cgj:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 2.15 Å

PDB-4chn:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 2 Å

PDB-4cho:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.7 Å

PDB-4chp:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.9 Å

PDB-4chq:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.95 Å

PDB-4chy:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.7 Å

PDB-4chz:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.8 Å

PDB-4cie:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.7 Å

PDB-4cif:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.8 Å

PDB-4cig:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.7 Å

PDB-4cj3:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.7 Å

PDB-4cj4:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.8 Å

PDB-4cj5:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.95 Å

PDB-4cje:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.9 Å

PDB-4cjf:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.9 Å

PDB-4cjk:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.75 Å

PDB-4cjl:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.77 Å

PDB-4cjp:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 2 Å

PDB-4cjq:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.7 Å

PDB-4cjr:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.8 Å

PDB-4cjs:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.8 Å

PDB-4cjt:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.71 Å

PDB-4cju:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.7 Å

PDB-4cjv:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.95 Å

PDB-4cjw:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.95 Å

PDB-4ck1:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.75 Å

PDB-4ck2:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.85 Å

PDB-4ck3:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.79 Å

PDB-4ovl:
Interrogating HIV integrase for compounds that bind- a SAMPL challenge
手法: X-RAY DIFFRACTION / 解像度: 1.7 Å

化合物

ChemComp-SO4:
SULFATE ION / 硫酸ジアニオン

ChemComp-ACY:
ACETIC ACID / 酢酸

ChemComp-GOL:
GLYCEROL / グリセロ-ル

ChemComp-O3N:
(2S)-2-(2-carboxyethyl)-6-{[{2-[(cyclohexylmethyl)carbamoyl]benzyl}(prop-2-en-1-yl)amino]methyl}-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid

ChemComp-HOH:
WATER

ChemComp-CL:
Unknown entry / クロリド

ChemComp-ZSW:
(R)-[2-[[(2R)-butan-2-yl]carbamoyl]phenyl]methyl-[[(2S)-5-carboxy-2-(2-carboxyethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]methyl]-prop-2-enyl-azanium

ChemComp-EDO:
1,2-ETHANEDIOL / エチレングリコ-ル

ChemComp-ZSV:
(R)-[(2S)-5-carboxy-2-(2-carboxyethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]methyl-[[2-[(4-methoxyphenyl)methylcarbamoyl]phenyl]methyl]-prop-2-enyl-azanium

ChemComp-ACT:
ACETATE ION / 酢酸イオン

ChemComp-2SS:
(2S)-6-[[[2-(cyclobutylmethylcarbamoyl)phenyl]methyl-prop-2-enyl-amino]methyl]-2-(3-hydroxy-3-oxopropyl)-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid

ChemComp-9NS:
(2S)-6-[[[2-(furan-2-ylmethylcarbamoyl)phenyl]methyl-prop-2-enyl-amino]methyl]-2-(3-hydroxy-3-oxopropyl)-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid

ChemComp-B0T:
(2S)-6-[[[2-[[(2S)-butan-2-yl]carbamoyl]phenyl]methyl-methyl-amino]methyl]-2-(3-hydroxy-3-oxopropyl)-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid

ChemComp-D0T:
(2S)-2-(3-hydroxy-3-oxopropyl)-6-[[methyl-[[2-[(phenylmethyl)carbamoyl]phenyl]methyl]amino]methyl]-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid

ChemComp-G0T:
(2S)-2-(3-hydroxy-3-oxopropyl)-6-[[[2-[(4-methoxyphenyl)methylcarbamoyl]phenyl]methyl-methyl-amino]methyl]-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid

ChemComp-QCH:
(2S)-6-[[[2-(cyclohexylmethylcarbamoyl)phenyl]methyl-methyl-amino]methyl]-2-(3-hydroxy-3-oxopropyl)-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid

ChemComp-DMS:
DIMETHYL SULFOXIDE / 2-チアプロパン2-オキシド / DMSO, 沈殿剤*YM

ChemComp-VL4:
(2S)-6-[[[2-(cyclobutylmethylcarbamoyl)phenyl]methyl-methyl-amino]methyl]-2-(3-hydroxy-3-oxopropyl)-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid

ChemComp-NFW:
(2S)-6-[[[2-(furan-2-ylmethylcarbamoyl)phenyl]methyl-methyl-amino]methyl]-2-(3-hydroxy-3-oxopropyl)-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid

ChemComp-O5U:
(2R)-6-[[(1R,2S)-2-(6-azanylhexanoylamino)-2,3-dihydro-1H-inden-1-yl]methyl]-2-(3-hydroxy-3-oxopropyl)-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid

ChemComp-IY7:
(2s)-6-[[(1r,2s)-2-(5-azanylpentanoylamino)-2,3-dihydro-1h-inden-1-yl]methyl]-2-(3-hydroxy-3-oxopropyl)-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid

ChemComp-3GM:
(2s)-6-[[(1r,2s)-2-(4-azanylbutanoylamino)-2,3-dihydro-1h-inden-1-yl]methyl]-2-(3-hydroxy-3-oxopropyl)-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid

ChemComp-V7H:
(2S)-2-(3-hydroxy-3-oxopropyl)-6-[[[2-[(phenylmethyl)carbamoyl]phenyl]methylamino]methyl]-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid

ChemComp-5EY:
(3R)-3-(3-hydroxy-3-oxopropyl)-6-[(E)-[(2R)-2-oxidanyl-2,3-dihydroinden-1-ylidene]methyl]-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid

ChemComp-EE2:
(2R)-2-(3-hydroxy-3-oxopropyl)-6-[(E)-[(2S)-2-oxidanyl-2,3-dihydroinden-1-ylidene]methyl]-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid

ChemComp-WOP:
5-[[methyl-[[(1S)-2-oxidanylidene-1-phenyl-2-[(phenylmethyl)amino]ethyl]carbamoyl]amino]methyl]-1,3-benzodioxole-4-carboxylic acid

ChemComp-OM3:
(R)-(4-CARBOXY-1,3-BENZODIOXOL-5-YL)METHYL-[[2-(CYCLOHEXYLMETHYLCARBAMOYL)PHENYL]METHYL]-METHYL-AZANIUM

ChemComp-7NV:
5-[[[(1S)-2-(butylamino)-2-oxidanylidene-1-phenyl-ethyl]carbamoyl-methyl-amino]methyl]-1,3-benzodioxole-4-carboxylic acid

ChemComp-S8Y:
5-[[[(1R)-2-(tert-butylamino)-2-oxidanylidene-1-phenyl-ethyl]carbamoyl-methyl-amino]methyl]-1,3-benzodioxole-4-carboxylic acid

ChemComp-8P3:
2-[(2-oxo-2,3-dihydro-1H-indol-1-yl)methyl]benzoic acid

ChemComp-UJ6:
5-{[(3S)-2-oxo-2,3-dihydro-1H-indol-3-yl]methyl}-1,3-benzodioxole-4-carboxylic acid

ChemComp-K5Q:
(2S)-6-[(E)-[(2E)-2-hydroxyimino-3H-inden-1-ylidene]methyl]-2-(3-hydroxy-3-oxopropyl)-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid

ChemComp-LOZ:
5-[[(1S,2R)-2-(4-azanylbutanoylamino)-2,3-dihydro-1H-inden-1-yl]methyl]-1,3-benzodioxole-4-carboxylic acid

ChemComp-NZL:
5-[[(1S,2S)-2-(6-azanylhexanoylamino)-2,3-dihydro-1H-inden-1-yl]methyl]-1,3-benzodioxole-4-carboxylic acid

ChemComp-ONZ:
2-(1,3-benzodioxol-4-ylcarbonylamino)ethanoic acid

ChemComp-U2Z:
[1-[2-(aminomethyl)phenyl]-5-methyl-pyrazol-3-yl]methanol

ChemComp-IMV:
5-[(2-oxo-2,3-dihydro-1H-indol-1-yl)methyl]-1,3-benzodioxole-4-carboxylic acid

ChemComp-CWU:
5-[[(1S,2R)-2-oxidanyl-2,3-dihydro-1H-inden-1-yl]methyl]-1,3-benzodioxole-4-carboxylic acid

ChemComp-C5Q:
5-(1H-indol-3-ylmethyl)-1,3-benzodioxole-4-carboxylic acid

ChemComp-H75:
2-(4-bromophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-3(2H)-one

ChemComp-Y7N:
5-[(E)-[(2S)-2-(6-azanylhexanoylamino)-2,3-dihydroinden-1-ylidene]methyl]-1,3-benzodioxole-4-carboxylic acid

ChemComp-JDX:
2-methoxy-6-[[[2-[(4-methoxyphenyl)methylcarbamoyl]phenyl]methyl-methyl-amino]methyl]benzoic acid

ChemComp-X0P:
2-methoxy-6-[[[3-[(4-methoxyphenyl)methylcarbamoyl]naphthalen-2-yl]methyl-methyl-amino]methyl]benzoic acid

ChemComp-E4F:
5-[[(1R,2S)-2-(5-azanylpentanoylamino)-2,3-dihydro-1H-inden-1-yl]methyl]-1,3-benzodioxole-4-carboxylic acid

ChemComp-S3G:
5-[(2S)-4-methyl-2-[(pyridin-4-ylcarbonylamino)methyl]pentyl]-1,3-benzodioxole-4-carboxylic acid

ChemComp-4VW:
5-[(2S)-2-[[(4-aminophenyl)carbonylamino]methyl]-4-methyl-pentyl]-1,3-benzodioxole-4-carboxylic acid

ChemComp-Q31:
5-[(2S)-2-[[2-(1H-imidazol-4-yl)ethanoylamino]methyl]-4-methyl-pentyl]-1,3-benzodioxole-4-carboxylic acid

ChemComp-RVN:
5-[(E)-(2-oxidanylidene-1H-indol-3-ylidene)methyl]-1,3-benzodioxole-4-carboxylic acid

ChemComp-H39:
5-[(2S)-4-methyl-2-{[(1H-pyrrol-3-ylacetyl)amino]methyl}pentyl]-1,3-benzodioxole-4-carboxylic acid

ChemComp-9PA:
5-[(2S)-2-{[(5-aminopentanoyl)amino]methyl}-4-methylpentyl]-1,3-benzodioxole-4-carboxylic acid

ChemComp-4D2:
5-[(2S)-4-methyl-2-[(pyridin-3-ylcarbonylamino)methyl]pentyl]-1,3-benzodioxole-4-carboxylic acid

ChemComp-VXO:
5-[(2S)-2-[[2-(1H-indol-3-yl)ethanoylamino]methyl]-4-methyl-pentyl]-1,3-benzodioxole-4-carboxylic acid

ChemComp-FYM:
2-methoxy-6-[[[6-[(4-methoxyphenyl)methylcarbamoyl]-1,3-benzodioxol-5-yl]methyl-methyl-amino]methyl]benzoic acid

ChemComp-L0Y:
6-[[[2-(cyclohexylmethylcarbamoyl)phenyl]methyl-methyl-amino]methyl]-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid

ChemComp-HLR:
1,2-benzoxazol-3-amine / 1,2-ベンゾイソオキサゾ-ル-3-アミン

ChemComp-JNS:
5-[(Z)-2-phenylethenyl]-1,3-benzodioxole-4-carboxylic acid

ChemComp-IV2:
5-chloranyl-4-methyl-1,3-benzothiazol-2-amine

ChemComp-CBJ:
6-[(5-bromo-2,3-dioxo-2,3-dihydro-1H-indol-1-yl)methyl]-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid

ChemComp-OM1:
(4-CARBOXY-1,3-BENZODIOXOL-5-YL)METHYL-[[2-[(4-METHOXYPHENYL)METHYLCARBAMOYL]PHENYL]METHYL]AZANIUM

ChemComp-NVU:
2-(1,2-benzoxazol-3-yl)ethanoic acid / 1,2-ベンゾイソオキサゾ-ル-3-酢酸

ChemComp-K1T:
5-[(2S)-2-{[(4-aminobutanoyl)amino]methyl}-4-methylpentyl]-1,3-benzodioxole-4-carboxylic acid

ChemComp-1TD:
3-[(E)-(2-oxidanylidene-1H-indol-3-ylidene)methyl]benzoic acid

由来
  • human immunodeficiency virus 1 (ヒト免疫不全ウイルス)
キーワードTRANSFERASE / STRUCTURE BASED DRUG DESIGN / DNA INTEGRATION / RNA-DIRECTED DNA POLYMERASE / HIV INTEGRASE

+
万見文献について

-
お知らせ

-
2022年2月9日: EMDBエントリの付随情報ファイルのフォーマットが新しくなりました

EMDBエントリの付随情報ファイルのフォーマットが新しくなりました

  • EMDBのヘッダファイルのバージョン3が、公式のフォーマットとなりました。
  • これまでは公式だったバージョン1.9は、アーカイブから削除されます。

関連情報:EMDBヘッダ

外部リンク:wwPDBはEMDBデータモデルのバージョン3へ移行します

-
2020年8月12日: 新型コロナ情報

新型コロナ情報

URL: https://pdbj.org/emnavi/covid19.php

新ページ: EM Navigatorに新型コロナウイルスの特設ページを開設しました。

関連情報:Covid-19情報 / 2020年3月5日: 新型コロナウイルスの構造データ

+
2020年3月5日: 新型コロナウイルスの構造データ

新型コロナウイルスの構造データ

関連情報:万見生物種 / 2020年8月12日: 新型コロナ情報

外部リンク:COVID-19特集ページ - PDBj / 今月の分子2020年2月:コロナウイルスプロテーアーゼ

+
2019年1月31日: EMDBのIDの桁数の変更

EMDBのIDの桁数の変更

  • EMDBエントリに付与されているアクセスコード(EMDB-ID)は4桁の数字(例、EMD-1234)でしたが、間もなく枯渇します。これまでの4桁のID番号は4桁のまま変更されませんが、4桁の数字を使い切った後に発行されるIDは5桁以上の数字(例、EMD-12345)になります。5桁のIDは2019年の春頃から発行される見通しです。
  • EM Navigator/万見では、接頭語「EMD-」は省略されています。

関連情報:Q: 「EMD」とは何ですか? / 万見/EM NavigatorにおけるID/アクセスコードの表記

外部リンク:EMDB Accession Codes are Changing Soon! / PDBjへお問い合わせ

+
2017年7月12日: PDB大規模アップデート

PDB大規模アップデート

  • 新バージョンのPDBx/mmCIF辞書形式に基づくデータがリリースされました。
  • 今回の更新はバージョン番号が4から5になる大規模なもので、全エントリデータの書き換えが行われる「Remediation」というアップデートに該当します。
  • このバージョンアップで、電子顕微鏡の実験手法に関する多くの項目の書式が改定されました(例:em_softwareなど)。
  • EM NavigatorとYorodumiでも、この改定に基づいた表示内容になります。

外部リンク:wwPDB Remediation / OneDepデータ基準に準拠した、より強化された内容のモデル構造ファイルが、PDBアーカイブで公開されました。

-
万見文献

EMDB/PDB/SASBDBから引用されている文献のデータベース

  • EMDB/PDB/SASBDBのエントリから引用されている文献のデータベースです
  • Pubmedのデータを利用しています

関連情報:EMDB / PDB / SASBDB / 万見 (Yorodumi) / EMN文献 / 新しいEM Navigatorと万見の変更点

他の情報も見る